ERBB2 and neoplasm: For the TCGA BRCA ER+/HER2- cohort (N = 552, Fig. 1) we assessed whether the clinical variables menopause status, AI treatment, tamoxifen treatment, tumour stage and age at diagnosis were associated with survival, with an event defined as first occurrence of a new tumour event or death.